-
PEG 400 Boosts Quercetin Exposure and Anti-Inflammation
2026-09-24
A rat pharmacokinetic and inflammation study found that PEG 400 increased plasma exposure to quercetin and its glucuronide metabolite, changed their tissue distribution, and enhanced quercetin’s effect in a paw-edema model. The combined imaging and in vitro experiments point to solubility, UGT1A9 activity, and BCRP/MRP2 transport as contributing factors, while leaving the relative importance of each mechanism unresolved.
-
In Vivo CD19 CAR T Cells for Lupus
2026-09-23
The reference study presents a CD5-targeted lipid nanoparticle that delivers CD19-directed CAR mRNA directly in vivo, generating functional CAR T cells without ex vivo cell manufacturing or lymphodepletion. In MRL/lpr mice, this approach depleted pathogenic B-cell populations, reduced autoimmune inflammation, and improved renal and dermal pathology, while highlighting important translational questions about durability, safety, and delivery.
-
FLAG tag Peptide (DYKDDDDK) in Viability Workflows
2026-09-23
Learn how SKU A6002, the FLAG tag Peptide (DYKDDDDK), can support recombinant protein detection and purification workflows that accompany cell viability, proliferation, and cytotoxicity assays. This scenario-based guide emphasizes assay compatibility, storage, resin-specific elution, and practical vendor-selection criteria.
-
Nutlin-3a Workflow for MDM2-P53 Research
2026-09-22
Nutlin-3a is a practical MDM2 inhibitor for connecting p53 pathway activation with cell-cycle control, apoptosis induction, and cancer-cell phenotyping. This workflow shows how to optimize dosing, separate apoptosis from ferroptosis, and extend findings into glioblastoma assays informed by the miR-18a/ALOXE3 axis.
-
Glioblastoma Apoptotic Priming and BH3-Mimetic Therapy
2026-09-21
Koessinger and colleagues show that glioblastoma, particularly its stem-like compartment, depends on elevated anti-apoptotic BCL-xL and MCL-1 activity. Their work links this apoptotic priming to therapeutic sensitivity and supports sequential BCL-2 family protein inhibition as a preclinical strategy for overcoming treatment resistance.
-
TPCA-1: A Translational IKK-2 Inhibitor Strategy
2026-09-21
TPCA-1 offers a selective way to interrogate IKK-2-dependent NF-κB signaling while keeping inflammatory transcription distinct from RIPK1-controlled apoptosis and necroptosis. This thought-leadership guide connects mechanistic biology, assay design, rheumatoid arthritis research, and translational decision-making without overstating what preclinical evidence can establish.
-
Exosomal Egr2 Protects Neurons After Ischemic Stroke
2026-09-20
This 2025 study identifies BMSC-derived exosomal Egr2 as a regulator of neuronal injury after oxygen-glucose deprivation/reoxygenation. Its mechanistic contribution is the connection of Egr2 transcriptional control of RNF8 with RNF8-dependent ubiquitination of DAPK1, providing a molecular explanation for the protective effects of BMSC exosomes in an in vitro ischemic-stroke model.
-
Eltanexor: From Nuclear Export to CRC Assays
2026-09-19
Eltanexor (KPT-8602) offers a mechanistically focused way to study XPO1 inhibition beyond cell viability. This article translates recent Wnt/β-catenin and colorectal cancer findings into practical assay-design decisions, controls, and interpretation strategies.
-
Lactate–HMGB1 Signaling in Polymicrobial Sepsis
2026-09-19
Yang and colleagues identify lactate as an active regulator of macrophage HMGB1 modification and exosomal release, rather than only a prognostic marker of sepsis severity. Their work connects lactate uptake, p300/CBP activity, GPR81–YAP–SIRT1 signaling, endothelial permeability, and survival in polymicrobial sepsis, while defining experimental opportunities for studying inflammatory mediator release.
-
TG003: A Rigorous Clk2 Assay Strategy
2026-09-18
TG003 is a Cdc2-like kinase inhibitor that connects splice-factor phosphorylation with Clk2-dependent platinum-resistance biology. This guide presents an assay framework for distinguishing alternative splicing modulation from DNA-repair and survival effects, while defining practical controls, handling parameters, and translational limitations.
-
BMS 599626 Dihydrochloride Workflow Guide
2026-09-18
Build reproducible EGFR/HER2 pathway experiments with BMS 599626 dihydrochloride, from dose-response design to phospho-receptor validation. This guide distinguishes established kinase biology from exploratory senescence applications and provides practical controls, timing, and troubleshooting steps for breast and lung cancer research.
-
Z-LEHD-FMK: Irreversible Caspase-9 Inhibitor
2026-09-17
Z-LEHD-FMK is an irreversible caspase-9 inhibitor for investigating mitochondria-mediated apoptosis, caspase activity measurement, and cytoprotection models. Its reported activity supports pathway-dissection studies, but it should not be interpreted as a pan-caspase inhibitor or as an antiviral agent.
-
Dual-Action Kinase Inhibitors and p38α Dephosphorylation
2026-09-17
The referenced bioRxiv study shows that selected kinase inhibitors can do more than block catalysis: they can also accelerate WIP1-mediated dephosphorylation of the p38α activation loop. Structural and biochemical experiments connect this effect to an inhibitor-stabilized activation-loop conformation, suggesting a route toward kinase inhibitors with an added phosphatase-directed mode of action.
-
Probenecid: MRP Inhibition and Neuroprotection
2026-09-16
Probenecid, also known as 4-(dipropylsulfamoyl)benzoic acid, is a research inhibitor of organic anion transporters, multidrug resistance-associated proteins, and pannexin-1 channels. Its strongest research rationale combines multidrug resistance reversal in leukemia models with neuroprotection in cerebral ischemia/reperfusion injury, while its concentration, transporter selectivity, and translational limits require careful assay controls.
-
Norovirus Co-opts NINJ1 for Selective Secretion
2026-09-15
Song and colleagues show that murine norovirus uses the host membrane-rupture factor NINJ1 to release the viral protein NS1 while also permitting broad damage-associated molecular pattern release. The study connects caspase-3 processing, NINJ1 recruitment to viral replication sites, and NS1 binding, establishing a mechanistic framework for unconventional viral protein secretion in vivo.